QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α

<strong></strong><em>The article presents results of study of inhibitor TNF<span class="st"> α</span> — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the rates of physical functioning were similar to it in healthy children the same age.</em><br /><em><strong>Key words: children, juvenile arthritis, quality of life, infliximab.</strong></em><br /><span style="text-decoration: underline;"><em>(<em><em><em>Voprosy sovremennoi pediatrii — </em></em></em>Current Pediatrics. 2009;8(3):<em>18-26</em>)</em>